Peter M. Voorhees, MD, of Atrium Health in Charlotte, North Carolina, discussed the emerging role of B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell treatment strategies in multiple myeloma presented at the 2019 ASH Annual Meeting. In particular, he discussed “exciting preliminary data” of a novel BCMA-bispecific antibody. The first-in-human study showed that a majority of patients are responding to therapy at higher dose levels. “With relatively short follow-up, the results are really quite impressive,” he said.
Home Conference Coverage American Society of Hematology (ASH) Annual Meeting 2019 “Impressive” Results in BCMA CAR T-Cell Therapy for Multiple Myeloma